Size | Price | Stock | Qty |
---|---|---|---|
25mg |
|
||
50mg |
|
||
100mg |
|
||
250mg |
|
||
500mg |
|
||
1g |
|
||
Other Sizes |
|
Purity: ≥98%
ML-193 (ML193; CID-1261822; CID1261822) is a novel and potent GPR55 (G protein-coupled receptor 55) antagonist with IC50 of 221 nM. Exhibiting >27-, >145- and >145-fold selectivity for GPR55 over CB1, GPR35 and CB2, respectively. As a novel cannabinoid receptor, CPR55 has been implicated.
Targets |
GPR55 ( IC50 = 221 nM )
|
---|---|
ln Vitro |
ML-193 (0.01-100 μM; pretreated for 15 min) has an IC50 of 0.22 μM, while ML186 (1 μM) inhibits β-arrestin trafficking induced by L-α-lysophophosphatidylinositol (LPI, 10 μM)[2].
ML-193 (0.01-10 μM; pretreated for 30 min) reduces the LPI-mediated ERK1/2 phosphorylation, with an IC50 of 0.2 μM in U2OS cells[2]. ML-193 (5 μM; pretreated for 30 min) reduces the increases in hNSC proliferation rates that GPR55 agonists cause[4]. ML-193 (5 μM; 10 d) reduces the increases in hNSC differentiation brought on by ML184[4]. |
ln Vivo |
ML193 (at 1 and 5 µg/rat; intrastriatal at a rate of 1 μL/min) improves motor coordination in PD rats and attenuates sensorimotor deficits and slip steps[3].
|
Animal Protocol |
Male Wistar rats (200-250 g) were induced experimental Parkinson by 6-hydroxydopamine (6-OHDA, 10 µg/rat)[3]
1 and 5 µg/rat Injected into the right striatum at a rate of 1 μL/min |
References |
|
Molecular Formula |
C28H25N5O4S
|
---|---|
Molecular Weight |
527.599
|
Exact Mass |
527.16
|
Elemental Analysis |
C, 63.74; H, 4.78; N, 13.27; O, 12.13; S, 6.08
|
CAS # |
713121-80-3
|
Appearance |
Solid powder
|
SMILES |
CC1=CC(=C2C(=C1)C(=CC(=N2)C3=CC=CC=N3)C(=O)NC4=CC=C(C=C4)S(=O)(=O)NC5=C(C(=NO5)C)C)C
|
InChi Key |
HTSLEZOTMYUPLU-UHFFFAOYSA-N
|
InChi Code |
InChI=1S/C28H25N5O4S/c1-16-13-17(2)26-22(14-16)23(15-25(31-26)24-7-5-6-12-29-24)27(34)30-20-8-10-21(11-9-20)38(35,36)33-28-18(3)19(4)32-37-28/h5-15,33H,1-4H3,(H,30,34)
|
Chemical Name |
N-[4-[(3,4-dimethyl-1,2-oxazol-5-yl)sulfamoyl]phenyl]-6,8-dimethyl-2-pyridin-2-ylquinoline-4-carboxamide
|
Synonyms |
CID 1261822; ML193; CID-1261822; CID1261822; ML 193; ML-193
|
HS Tariff Code |
2934.99.9001
|
Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
Solubility (In Vitro) |
DMSO: ~33.3 mg/mL (~63.2 mM)
|
---|---|
Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80: Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 :Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400  (Please use freshly prepared in vivo formulations for optimal results.) |
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 1.8954 mL | 9.4769 mL | 18.9538 mL | |
5 mM | 0.3791 mL | 1.8954 mL | 3.7908 mL | |
10 mM | 0.1895 mL | 0.9477 mL | 1.8954 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Antagonist Activity of ML191, ML192 and ML193. Biochemistry . 2013 Dec 31;52(52):9456-69. td> |
Molecular electrostatic potential maps of ML191, ML192 and ML193 are shown here in the top row. Biochemistry . 2013 Dec 31;52(52):9456-69. td> |